Piper Sandler Reiterates Buy as Seralutinib Momentum Boosts Gossamer (GOSS) Multibagger Case

Gossamer Bio Inc. (NASDAQ:GOSS) is one of the best multibagger stocks to invest in right now. The company’s focus lies on its lead asset, Seralutinib, which targets pulmonary arterial hypertension (PAH), a severe condition with limited treatment options. Investor enthusiasm for the stock has grown markedly this year. It was trading around $1 at the start of the year and has since climbed to $2.50, delivering nearly 180% returns year-to-date.

In line with that performance, analyst sentiment has also strengthened. Gossamer Bio Inc. (NASDAQ:GOSS) received a Buy rating from Yasmeen Rahimi of Piper Sandler on September 5, with a price target of $15 reiterated.

The call comes shortly after H.C. Wainwright’s Patrick Trucchio reaffirmed his Buy rating on August 19 with a $10 target, highlighting confidence in the company’s lead candidate, seralutinib.

Trucchio’s report highlighted that the recent literature reviews and trial extensions have reinforced optimism around seralutinib. Data from the open-label extension of the Phase 2 study showed benefits held-up for 72 weeks, including reduced pulmonary vascular resistance and improved six-minute walk distance. These findings suggest the drug may have disease-modifying potential rather than offering only short-term relief.

He also pointed to the possibility of using seralutinib in combination with other therapies, which could broaden its role in pulmonary treatment. The upcoming Phase 3 PROSERA trial, with results expected in February 2026, remains the next major catalyst.

Gossamer Bio Inc. (NASDAQ:GOSS) is a clinical-stage biopharmaceutical company developing therapies for pulmonary and cardiovascular diseases.

While we acknowledge the potential of GOSS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Most Shorted Stocks Right Now and 10 Best High Beta Stocks To Buy Now.

Disclosure: None. This article is originally published at Insider Monkey.